

# 1 **Clinical performance validation of the STANDARD G6PD Test: A multi-** 2 **country pooled analysis**

3 Wondimagegn Adissu<sup>1,2</sup>, Marcelo Brito<sup>3,4</sup>, Eduardo Garbin<sup>5</sup>, Marcela Macedo<sup>5</sup>, Wuelton Monteiro<sup>3,4</sup>,  
4 Sandip Mukherjee<sup>6</sup>, Jane Myburg<sup>7</sup>, Mohammad Shafiul Alam<sup>8</sup>, Germana Bancone<sup>9, 10</sup>, Pooja Bansil<sup>11</sup>,  
5 Sampa Pal<sup>11</sup>, Abhijit Sharma<sup>11</sup>, Stephanie Zobrist<sup>11</sup>, Andrew Bryan<sup>12</sup>, Cindy S Chu<sup>9,10</sup>, Santasabuj Das<sup>6</sup>,  
6 Gonzalo J Domingo<sup>11</sup>, Amanda Hann<sup>7</sup>, James Kublin<sup>12,13</sup>, Marcus VG Lacerda<sup>3,4,14</sup>, Mark Layton<sup>7</sup>,  
7 Benedikt Ley<sup>15</sup>, Sean C Murphy<sup>16,17</sup>, Francois Nosten<sup>9,10</sup>, Dhélio Pereira<sup>5,18</sup>, Ric N Price<sup>10,15</sup>, Arunansu  
8 Talukdar<sup>19</sup>, Daniel Yilma<sup>2,20</sup>, Emily Gerth-Guyette<sup>11\*</sup>

## 9 **Affiliations:**

- 10 1. School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia
- 11 2. Clinical Trial Unit, Jimma University, Jimma, Ethiopia
- 12 3. Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas,  
13 Brazil
- 14 4. Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil
- 15 5. Centro de Pesquisa Em Medicina Tropical (CEPEM), Porto Velho, Rondônia, Brazil
- 16 6. National Institute of Cholera and Enteric Diseases, Kolkata, India
- 17 7. Special Haematology Laboratory, Hammersmith Hospital, London, United Kingdom
- 18 8. Infectious Diseases Division, International Centre for Diarrheal Diseases Research, Bangladesh  
19 (icddr,b), Mohakhali, Dhaka, Bangladesh
- 20 9. Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of  
21 Tropical Medicine, Mahidol University, P.O. Box 46, 68/31 Bann Tung Road, Mae Sot, 63110,  
22 Thailand.
- 23 10. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of  
24 Oxford, Oxford, United Kingdom
- 25 11. Diagnostics, PATH, Seattle, Washington, United States of America
- 26 12. Departments of Laboratory Medicine and Microbiology, University of Washington School of  
27 Medicine, Seattle, Washington, United States of America
- 28 13. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle,  
29 Washington, United States of America
- 30 14. Instituto Leônidas & Maria Deane (ILMD), Fiocruz, Manaus, Amazonas, Brazil
- 31 15. Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin  
32 University, Darwin, Australia

- 33 16. Department of Laboratory Medicine and Pathology, University of Washington, Seattle,  
34 Washington, United States of America
- 35 17. Center for Emerging and Reemerging Infectious Diseases, University of Washington, Seattle,  
36 Washington, United States of America
- 37 18. Universidade Federal de Rondônia (UNIR), Porto Velho, Rondônia, Brazil
- 38 19. Kolkata Medical College Hospital, India
- 39 20. Department of Internal Medicine, Jimma University, Jimma, Ethiopia

40 **Corresponding author:** Emily Gerth-Guyette

41

## 42 **Abstract**

43 **Introduction:** Screening for G6PD deficiency can inform disease management including malaria.  
44 Treatment with the antimalarial drugs primaquine and tafenoquine can be guided by point-of-care testing  
45 for G6PD deficiency.

46 **Methods and Findings:** Data from similar clinical studies evaluating the performance of the  
47 STANDARD™ G6PD Test (SD Biosensor, South Korea) conducted in Bangladesh, Brazil, Ethiopia,  
48 India, Thailand, the United Kingdom, and the United States were pooled. Test performance was assessed  
49 in a retrospective analysis on capillary and venous specimens. All study sites used spectrophotometry for  
50 reference G6PD testing, and either the HemoCue or complete blood count for reference hemoglobin  
51 measurement.

52 The sensitivity of the STANDARD™ G6PD Test using the manufacturer thresholds for G6PD deficient  
53 and intermediate cases in capillary specimens from 4212 study participants was 100% (95% Confidence  
54 Interval (CI): 97.5%–100%) for G6PD deficient cases with <30% activity and 77% (95% CI 66.8%–  
55 85.4%) for females with intermediate activity between 30%–70%. Specificity was 98.1% (95% CI  
56 97.6%–98.5%) and 92.8% (95% CI 91.6%–93.9%) for G6PD deficient individuals and intermediate  
57 females, respectively. The majority (12/20) of G6PD intermediate females with false normal results had  
58 activity levels >60% on the reference assay. Negative predictive values for females with G6PD activity  
59 >60% was 99.6% (95% CI 99.1%–99.8%) on capillary specimens. Test sensitivity among 396 *P. vivax*  
60 malaria cases was 100% (69.2%–100.0%) for both deficient and intermediate cases. In the study  
61 population, a high proportion of those classified as G6PD deficient or intermediate resulted from true  
62 normal cases. Despite this, the majority cases would receive the correct medication and no true G6PD  
63 deficient cases would be treated inappropriately.

64 **Conclusions:** The STANDARD G6PD Test enables safe access to drugs which are contraindicated for  
65 individuals with G6PD deficiency. Operational considerations will inform test uptake in specific settings.

66 **Keywords:** G6PD enzyme activity, malaria, *Plasmodium vivax*, diagnostic performance

## 67 **Introduction**

68 The glucose-6-phosphate dehydrogenase (G6PD) enzyme plays an essential role in the protection of red  
69 blood cells against damage from oxidative stress. This enzyme is one of the most polymorphic in the  
70 human genome, leading to many mutations resulting in the enzymopathy G6PD deficiency.<sup>1</sup> G6PD  
71 deficiency is one of the most common human genetic disorder affecting an estimated 500 million people  
72 worldwide.<sup>1</sup> The red blood cells of individuals with this condition have decreased G6PD enzyme activity  
73 and are more susceptible to hemolysis as a result of an oxidative challenge. Common oxidative challenges  
74 include from foods such as fava beans,<sup>2</sup> infections such as SARS-CoV-2 infection<sup>3,4</sup> and typhoid, and  
75 medications such as rasburicase<sup>5</sup> and 8-aminoquinoline-based anti-malaria drugs used for radical cure  
76 treatment of *Plasmodium vivax* malaria (e.g., primaquine and tafenoquine).<sup>6,7</sup> G6PD deficiency is also a  
77 strong predictor of pathologic neonatal jaundice and potential for life-threatening kernicterus in  
78 newborns.<sup>8-10</sup>

79 Until recently, diagnosis of G6PD deficiency has primarily relied on moderate to high complexity  
80 laboratory assays. In practice, the implementation of such tests has been challenging as described in  
81 recent publications from the College of American Pathologists.<sup>11,12</sup> More recently, point-of-care (POC)  
82 tests for G6PD deficiency are emerging, providing opportunities to expand testing to populations without  
83 access to laboratory-based assays.<sup>13</sup> Such tests are particularly important in the context of malaria case  
84 management, given the limited infrastructure in settings where malaria patients typically seek care. At a  
85 global level, the World Health Organization recommends G6PD testing prior to the administration of  
86 radical cure treatments for *P. vivax* malaria.<sup>14</sup> However, among malaria-endemic countries, policies and  
87 practices related to G6PD testing and radical cure implementation vary significantly, based in part on the  
88 underlying epidemiology of G6PD deficiency as well as barriers to access and adoption.<sup>15</sup>

89 POC tests for G6PD deficiency include both qualitative rapid tests, as well as quantitative biosensor tests  
90 that provide numeric results of patients' G6PD activity levels. Two qualitative tests have shown promise  
91 under laboratory conditions, but have limitations in field conditions, including challenges with  
92 temperature correction and the inability to identify females with intermediate G6PD activity arising from  
93 a heterozygous *g6pd<sub>normal</sub>/g6pd<sub>deficient</sub>* genotype.<sup>16-18</sup> The STANDARD G6PD Test (SD Biosensor,  
94 Republic of Korea) is a quantitative enzymatic colorimetric assay intended to aid in the detection of  
95 G6PD deficiency at the POC. The test measures G6PD enzyme activity normalized by hemoglobin (Hb)  
96 (U/g Hb) and total-hemoglobin concentration (g/dL) on 10 µl of capillary or venous blood samples.  
97 Results are provided within two minutes on a portable, handheld analyzer and used to classify individuals  
98 as G6PD normal, intermediate, or deficient according to the manufacturer's recommended thresholds.

99 This classification can be used to inform clinical decision-making, particularly as it relates to priority  
100 applications, such as malaria case management.

101 Cross-sectional diagnostic accuracy studies have been conducted in a wide range of settings and  
102 locations, to evaluate the performance of the STANDARD G6PD Test.<sup>19–22</sup> Pooling data from these  
103 studies allows for a robust diagnostic performance analysis across diverse populations representative of  
104 multiple contexts and use cases for POC G6PD testing. Our aim was to 1) present these data for the  
105 STANDARD G6PD Test, 2) explore how a common set of thresholds to classify G6PD deficient or  
106 intermediate individuals with POC testing can be applied across populations, and 3) consider the  
107 implications of the test performance on 8-aminoquinoline malaria treatment regimens.

## 108 **Materials and Methods**

109 Data were included from similar cross-sectional diagnostic accuracy studies conducted in seven countries:  
110 Bangladesh,<sup>21</sup> Brazil,<sup>20</sup> Ethiopia (unpublished), India (unpublished), Thailand,<sup>19</sup> the United Kingdom,<sup>22</sup>  
111 and the United States<sup>19,22</sup> (Supplementary Table 1). Collectively, these studies span a varied range of  
112 underlying G6PD epidemiology and malaria incidence. The primary objective of all studies was to  
113 evaluate the performance of the STANDARD G6PD Test for its ability to identify G6PD normal,  
114 intermediate, and deficient individuals, and to evaluate the test’s ability to measure hemoglobin  
115 concentration. The performance of the STANDARD G6PD Test on capillary and/or venous specimens  
116 was compared to G6PD reference values normalized by hemoglobin from venous specimens tested with a  
117 spectrophotometer. Only one study (Thailand) used frozen venous specimens.<sup>19</sup> The performance of the  
118 STANDARD G6PD Test in the measurement of hemoglobin concentration was also compared to a  
119 complete blood count from automated hematology analyzers where available, and/or to results from  
120 venous specimens on the HemoCue 201+ system.

## 121 **Ethical considerations and study populations**

122 All studies involving human subjects were reviewed by relevant ethics committees (Supplementary Table  
123 1) and written informed consent to participate was obtained for all participants. Varying recruitment  
124 methods appropriate to each site were employed to ensure study populations that were both representative  
125 of intended use settings—including malaria-endemic settings and blood donation centers—as well as of  
126 G6PD activity levels across the dynamic range (Supplementary Table 1).

## 127 **Testing**

128 Supplementary Figure 1 summarizes the tests and overall workflow of the included studies.

129 STANDARD G6PD Test. The STANDARD G6PD Test was performed in all studies on non-  
130 anticoagulated capillary and/or venous K<sub>2</sub>EDTA whole blood as per the manufacturer's instructions. In  
131 addition to the analyzer, test components include disposable test strips (Test Devices), disposable blood  
132 transfer tubes (Ezi Tubes+), extraction buffer vials, and a lot-specific code chip used for calibration. For  
133 testing on capillary specimens, 10 µl of blood was collected via fingerprick using a disposable Ezi Tube+  
134 and mixed with the extraction buffer. Next, a second, clean Ezi Tube+ was used to transfer 10 µl of the  
135 mixed specimen to the Test Device, which is inserted into the analyzer. When run on venous specimens,  
136 10 µl of blood was transferred to the buffer solution using either a professional pipette<sup>20-22</sup> or the Ezi  
137 Tube+ sample collector.<sup>19,22</sup> After two minutes, the test reports quantitative measurements of G6PD  
138 activity in U/g Hb and hemoglobin (g/dL). The manufacturer's recommended G6PD activity thresholds  
139 were applied to determine G6PD status based on the quantitative test result: 4.0 U/g Hb and 6.0 U/g Hb  
140 for G6PD deficient (≤30% activity) and intermediate (≤70% activity), respectively.

141 Reference G6PD testing. In all studies, spectrophotometry was used as the reference assay on venous  
142 K<sub>2</sub>EDTA whole blood, using a temperature-regulated instrument. Either the Pointe Scientific (Canton,  
143 MI, catalog number G7583) or the Trinity Biotech (Bray, Ireland) G6PD reagent kits were used. All  
144 G6PD activity results were normalized for hemoglobin concentration and are presented in U/g Hb.

145 Hemoglobin measurement. Hemoglobin was measured according to the following methods:

- 146 • *Complete blood count (CBC).* In the Bangladesh, Brazil, Ethiopia, India, Thailand, and US (2021)  
147 studies in Pennsylvania and Washington,<sup>19-22</sup> total hemoglobin concentration (g/dL) was  
148 determined using a CBC on an automated hematology analyzer. This measurement served as the  
149 reference method for the measurement of Hb concentration and was used to normalize the  
150 reference assay for G6PD activity.
- 151 • *HemoCue 201+.* With the exception of the Bangladesh and Thailand studies, the HemoCue Hb  
152 201+ System was also performed on non-anticoagulated capillary blood and/or venous K<sub>2</sub>EDTA  
153 blood as a comparative measure of hemoglobin concentration in g/dL according to the  
154 manufacturer instructions. For studies where CBC was not available, the HemoCue 201+  
155 measurement was used to normalize the reference assay for G6PD activity.

156 Malaria testing. In three studies, the malaria status of participants was assessed by the standard method at  
157 each site—either microscopy (Brazil) or rapid diagnostic test (Ethiopia and India).

158 **Contrived specimen study**

159 Lastly, data are also presented for a contrived specimen study<sup>22</sup> that included a panel of 90 specimens  
160 spanning critical G6PD activity thresholds developed using heat abrogation and following a method  
161 adapted from the UK National External Quality Assurance Services G6PD scheme.<sup>23</sup> Five contrived  
162 specimens representing a broad hemoglobin concentration range were also developed using plasma-level  
163 adjustment. These 95 samples underwent blinded testing with the STANDARD G6PD Test and reference  
164 assay.

## 165 **Statistical methods**

166 Due to the observed inter-laboratory variability of the G6PD reference assay,<sup>11,22</sup> absolute G6PD values  
167 were normalized for each laboratory conducting the reference assay in each study.<sup>24-26</sup> Reference G6PD  
168 activity values were expressed as the percentage of each site's adjusted male median (AMM). For the  
169 majority of studies, the AMM was calculated from a subset of randomly selected males (n=36) with  
170 normal G6PD status as determined by each laboratory's reference range. These 36 males were  
171 subsequently excluded from the analytical population for the performance analysis. In the UK study, 39  
172 males were used to calculate the AMM. In the Bangladesh study, the AMM was calculated from the  
173 median activity of all known G6PD normal participants. For the Thai study, the AMM was calculated as  
174 described in Domingo et al. (2013),<sup>27</sup> wherein all males with reference G6PD activity  $\leq 10\%$  of the male  
175 median were excluded, and a new median activity was determined and used to normalize the reference  
176 data. A Kruskal Wallis test was used to compare medians between groups. Next, categorical thresholds  
177 were used to classify G6PD deficient cases (males and females with  $\leq 30\%$  activity), and females with  
178 intermediate activity ( $> 30\%$  and  $\leq 70\%$  activity).

179 Using pooled data from across all included studies, receiver operating characteristic (ROC) curves were  
180 generated to assess the ability of the test to discriminate G6PD deficient males and females, G6PD  
181 intermediate females, and G6PD normal males and females.

182 The pooled performance of the STANDARD G6PD Test against the spectrophotometric reference test for  
183 each specimen type was determined by calculating the test's sensitivity and specificity, and 95%  
184 confidence interval (CIs) to diagnose individuals G6PD status at the 30% and 70% thresholds.<sup>27</sup> For the  
185 purposes of this analysis, G6PD deficient and intermediate results by the reference assay were considered  
186 as true "positive", and G6PD normal results were considered as true "negatives." Overall agreement  
187 between the STANDARD G6PD Test and reference assay in the classification of normal, intermediate,  
188 and deficient G6PD activity levels was calculated and Kappa coefficients were determined at the same  
189 thresholds. Agreement was assessed for the STANDARD G6PD Test's T-Hb measurement against the

190 reference CBC assay results where available, using clinically-relevant thresholds for anemia established  
191 by the World Health Organization (WHO) (Supplementary Table 2).<sup>28</sup>

192 All statistical analyses were performed using Stata® 15.0 (StataCorp, College Station, TX).

193 To explore the implications of these results for malaria case management, the eligibility of the pooled  
194 study population for radical cure treatment regimens was considered. These eligibility criteria were based  
195 on the WHO recommendations regarding administration of primaquine for preventing relapse<sup>14</sup> as well as  
196 the product label for tafenoquine (Supplementary Table 3). Across the study population, G6PD  
197 classification by the reference assay was compared to G6PD classification by the SD Biosensor test. Next,  
198 theoretical treatment eligibility among the study population was calculated based on the results of both  
199 the reference assay and the STANDARD G6PD Test, with the former considered as the gold standard and  
200 true discriminating test while the latter was considered as the test that would determine treatment status.  
201 Based on the concordance or discordance between methods, participants were considered as either  
202 correctly or incorrectly receiving or being excluded from the recommended treatment algorithm outcome.  
203 Results are presented separately for two different treatment algorithms: 1) primaquine only, and 2)  
204 tafenoquine and primaquine, with those who were considered ineligible for tafenoquine then considered  
205 for primaquine eligibility. No other treatment eligibility criteria (e.g., age, pregnancy, anemia status) were  
206 considered as part of the calculation.

## 207 **Results**

208 Data from 4,212 capillary specimens and 4,844 venous specimens were included in the analysis (Table 1).  
209 The overall population was split evenly between males and females. The majority of participants with  
210 available data had either no or mild anemia. A total of 550 patients with confirmed malaria were included  
211 in the analysis.

### 212 **G6PD activity distribution**

213 The site-specific AMMs are reported in Supplementary Table 4. Study-specific median G6PD values and  
214 interquartile ranges (IQRs) for all normal males in the analytical populations on both the reference assay  
215 and the STANDARD G6PD Test on capillary and venous specimens are presented in Figure 1 and  
216 Supplementary Table 5. On the reference assay, the G6PD median ranged from 6.8 U/g Hb to 11.9 U/g  
217 Hb, as compared to 6.7 U/g Hb to 11.3 U/g Hb on the STANDARD G6PD Test. Overall, the G6PD  
218 median of the STANDARD G6PD Test was within a 1.5 U/g Hb range, with the exception of one of the  
219 US studies.<sup>19</sup> No correlation was observed between the reference assay G6PD normal male median and  
220 that of the STANDARD G6PD test across studies (data not shown). In Brazil and India, the study



221 population was recruited from those seeking care for malaria (Supplementary Table 1) and included a  
222 sufficient number of *P. vivax* cases among normal males. There was no significant difference in the AMM  
223 between malaria negative males and *P. vivax* positive males (Table 2). Among G6PD normal males, the  
224 median G6PD activity was significantly lower for *P. vivax* positive males compared to malaria negative  
225 males at the Kolkata, India, site, but not at the Porto Velho, Brazil, site.

226 Based on the 30% and 70% activity thresholds, data were available for 266 G6PD deficient, 233 G6PD  
227 intermediate, and 4,520 G6PD normal specimens (Table 1). The pooled prevalence for G6PD deficient  
228 and intermediate cases in the capillary sample analytical population was 3.4% and 2.1 %, respectively  
229 (Supplementary Table 6). The pooled prevalence for G6PD deficient and intermediate cases in the venous  
230 blood analytical population was 5.4% and 4.7 %, respectively (Supplementary Table 6). Supplementary  
231 Figure 2 presents the distribution of G6PD activities in the study population according to the reference  
232 assay and the STANDARD G6PD Test for both males and females.

### 233 **Pooled clinical performance of the STANDARD G6PD Test for G6PD**

234 ROC curves (Supplementary Figure 3) and associated performance characteristics (Supplementary Table  
235 7) show that the test performed well in detecting deficient individuals at the 30% activity threshold; the  
236 area under the curve (AUC) was 0.998 and 0.997 for capillary and venous specimens, respectively. At the  
237 70% threshold for intermediate females, AUC was 0.909 for capillary and 0.954 for venous specimens.

238 Table 3 summarizes the pooled diagnostic performance of the STANDARD G6PD Test for identifying  
239 G6PD deficient males and females, and females with intermediate G6PD activity, by specimen type.

240 Overall, at the 30% threshold, the test had a sensitivity of 100% for both specimen types. The specificity  
241 was 96.7% (95% CI 96.1%–97.2%) for combined venous and contrived specimens and 98.1% (95% CI  
242 97.6%–98.5%) for capillary specimens. For females with intermediate G6PD activity levels, the  
243 sensitivity was 77.0% on capillary specimens (95% CI 66.8%–85.4%), 86.6% on venous specimens  
244 excluding contrived (95% CI 80.6%–91.3%), and 89.0% on venous specimens including contrived (95%  
245 CI 85.4%–93.6%). Specificity was 92.8% for capillary specimens (95% CI 91.6%–93.9%), 94.9% for  
246 venous specimens without contrived (95% CI 93.3%–95.3%), and 93.9% for venous specimens including  
247 contrived (95% CI 92.8%–94.9%). Overall agreement was 94.8% for capillary and venous specimens, and  
248 93.8% for venous and contrived specimens combined (Supplementary Table 6).

249 All true deficient individuals were correctly identified by the STANDARD G6PD Test on both venous  
250 and capillary specimens and false normal results were only observed for females with intermediate G6PD  
251 activity (Figure 2; Table 4). On venous specimens, 10% (23/230) of intermediate females were  
252 misclassified as normal, compared to 25% (20/87) on capillary specimen (Table 4). However, the

253 majority (60%, 12/20) of these capillary discordant results were attributed to females with reference  
254 G6PD activity greater than 60% and only two samples had G6PD activities between 40 and 50%.  
255 (Supplementary Table 8; Table 5; Supplementary Figure 4). Negative predictive values for females with  
256 >60% reference activity were 99.6% and 99.5% for capillary and venous specimens (without contrived),  
257 respectively (Table 3; Table 5). In contrast, false positive results (particularly for intermediates) occurred  
258 in 6% (120/1934) of G6PD normal females who were misclassified as intermediate and 1.5% (34/2178)  
259 of G6PD normal males who were misclassified as deficient on capillary specimens.

#### 260 **Pooled clinical performance of the STANDARD G6PD Test for G6PD among *P. vivax* confirmed** 261 **cases**

262 Among participants with *P. vivax* malaria, on both capillary and venous specimens, sensitivity was 100%  
263 (95% CI 69.2%–100%) at the 30% threshold, with specificities of 99.0% (95% CI 97.4%–99.7%) and  
264 97.7% (95% CI 95.6%–98.9%) for capillary and venous specimens, respectively (Table 3). However, it  
265 should be noted that this is based on a small number of deficient and intermediate cases ( $\leq 10$ ) within this  
266 population.

#### 267 **Pooled clinical performance of the STANDARD G6PD Test for hemoglobin**

268 Linear regression of the STANDARD G6PD Test's hemoglobin result as compared to the hemoglobin  
269 result on the reference CBC is shown in Supplementary Figure 5, by specimen type. R-squared  
270 correlation values are 0.73 and 0.77 for capillary and venous specimens, respectively. Supplementary  
271 Table 9 presents the agreement between the STANDARD G6PD Test's anemia classification on both  
272 capillary and venous specimens as compared to the CBC results. Overall percent agreement between  
273 methods was 90.3% (95% CI 89.0%–91.5%) for capillary specimens and 94.3% (95% CI 93.2%–95.2%)  
274 for venous specimens (excluding contrived). None of the participants with severe anemia (Hb <7.0 g/dL  
275 for children 6-59 months of age or <8.0 g/dL for all other groups, n=44) were misclassified as non or mild  
276 anemia on either capillary or venous blood.

#### 277 **Implications for malaria treatment**

278 The STANDARD G6PD test results on capillary specimens were used to calculate the implications of the  
279 test performance on eligibility to different radical cure treatment options. Figures 3A and 3B illustrate a  
280 scenario where only daily primaquine radical cure regimen is available to males and females with G6PD  
281 activity greater than 30%. Based on the results of the STANDARD G6PD test, 94.8% (3993/4212) of the  
282 participants, representing all G6PD normal and intermediate participants, would be eligible for standard  
283 daily primaquine according to WHO guidelines and correctly provided primaquine based on the

284 concordance between the reference and POC test. Conversely, 5.2% (219/4212) would be excluded from  
285 standard primaquine treatment (Figure 3B). No G6PD deficient participants would be prescribed  
286 primaquine, but 1.8% (76/4212) males and females with intermediate and normal G6PD activity would be  
287 excluded from the daily treatment regimen (Figure 3B; Supplementary Table 10).

288 Figures 3C and 3D illustrate a scenario where both daily primaquine and single dose tafenoquine are  
289 available and tafenoquine is only available to males and females with G6PD activity greater than 70%.  
290 Based on the POC STANDARD G6PD test results 87.1% (3668/4212) of participants in the study  
291 population would be eligible for single dose radical cure (Figure 3C). One percent (43/4212) of the  
292 population with G6PD activity  $\leq 70\%$  would receive tafenoquine. These were 23 males and 20 females  
293 with G6PD activity between 30-70%, with a median G6PD activity of 63%. This analysis found that 7.7%  
294 of the population (168 males and 157 females) had a STANDARD G6PD Test result between 4 and 6 U/g  
295 Hb and would be eligible for standard daily primaquine all of these had G6PD activity  $> 30\%$ . Of these,  
296 6.5 % of the total population (153 males and 120 females) had a reference G6PD activity  $>70\%$  and could  
297 have been treated with tafenoquine (Figure 3D; Supplementary Table 10).

## 298 **Discussion**

299 In this paper, performance data for the STANDARD G6PD POC test for G6PD deficiency, was  
300 consolidated from multiple studies conducted on both capillary and venous specimens across seven  
301 countries, representing diverse settings and use cases for G6PD testing.

### 302 **Application of universal thresholds**

303 Performance estimates for the STANDARD G6PD Test were calculated by applying a single set of  
304 thresholds for G6PD deficiency and female intermediate activity in U/g Hb, as indicated by the  
305 manufacturer's instructions for use. For the reference assay, site-specific adjusted male medians were  
306 used to normalize results and establish 30% and 70% G6PD activity thresholds for defining deficient,  
307 intermediate, and normal cases. The male median G6PD activity on the POC test was more consistent  
308 across sites and specimen types—with the exception of one US site—in comparison to the reference  
309 assay, which showed greater site-to-site variability. Inter-site variability in the male median G6PD  
310 activity as defined by spectrophotometry has been described previously,<sup>25,29</sup> and is apparent even between  
311 sites testing the same specimens.<sup>22</sup> Site-to-site reproducibility of the STANDARD G6PD Test conducted  
312 on commercially available controls also has decreased variability compared to the reference assay  
313 conducted on the same control reagents in the same laboratories.<sup>30</sup> However, it is important to note with  
314 respect to the medians and thresholds that the populations of the studies in this analysis largely comprised  
315 of adults and children over the age of two. Only one study (in the United Kingdom) included few

316 newborn samples. Using the STANDARD G6PD Test for newborn screening applications will require the  
317 use of higher G6PD threshold values to account for the higher G6PD activity among newborns.<sup>31-34</sup> A  
318 recent study conducted in Thailand with the STANDARD G6PD Test on 307 cord blood samples showed  
319 good performance as long as the thresholds are adjusted to address the higher median G6PD activities in  
320 newborns.<sup>35</sup> A recent report suggests that malaria infection may also result in increased G6PD activity  
321 when looking across all malaria in deficient and intermediate cases.<sup>36</sup> However, in our analysis, there was  
322 no overall change in G6PD activity when comparing *P. vivax*-infected and uninfected males with normal  
323 G6PD activity. The male median G6PD value on the STANDARD G6PD test is statistically consistent  
324 across varied contexts and populations (aged two years and older), including in malaria-endemic settings,  
325 with the exception of newborns.

326

### 327 **Clinical implications for malaria case management**

328 From a safety perspective, the sensitivity and negative predictive values of POC G6PD tests to identify  
329 G6PD deficient and intermediate cases are critical to minimize adverse reactions to drugs that are  
330 contraindicated in individuals with G6PD deficiency. This is particularly relevant for the test's use in  
331 malaria case management, as standard 14-day primaquine regimens used for the radical cure of *P. vivax*  
332 malaria are not recommended for G6PD deficient males and females,<sup>37,38</sup> and safety of higher dose  
333 regimens among G6PD intermediate females is also a concern.<sup>39</sup> Additionally, tafenoquine is the first  
334 drug to indicate a threshold G6PD activity (70%) on its label, above which data indicates that it is  
335 considered safe to prescribe for radical cure.<sup>24,40</sup> The calculations above suggest that the use of the  
336 STANDARD G6PD Test at the point of care reduce risk of drug related hemolysis and so facilitate  
337 appropriate provision of treatment, in line with WHO and global treatment guidelines.

338 The STANDARD G6PD Test showed good performance both on capillary and venous samples for G6PD  
339 deficiency when applying the manufacturer's universal thresholds, and no G6PD deficient cases were  
340 misclassified as normal, which ensures G6PD deficient malaria patients will receive correct primaquine  
341 regimens. In fact, the STANDARD G6PD Test tends toward overestimation of G6PD deficiency at the  
342 deficient and intermediate thresholds as compared to the reference assay (Supplementary Table 6).

343 The test's sensitivity decreased for females with intermediate activity. However, most of the false normal  
344 results were attributed to females with G6PD activities >60%, (and all of whom had activities >40%),  
345 which means that they are less likely to experience severe hemolysis as the potential for severe clinical  
346 outcomes increases among those with more severe deficiency (i.e., a low percent G6PD activity). The  
347 negative predictive values for females with G6PD reference activity >60% is good at 99.6% and 99.5%

348 for both capillary and venous specimens, respectively. Among the almost 400 *P. vivax* cases included in  
349 this analysis, none of the deficient or intermediate cases were incorrectly classified as normal by the  
350 STANDARD G6PD Test. However, it should be noted that very few deficient and intermediate *P. vivax*-  
351 positive cases were included in this sample.

352 Of note, challenges associated with false normal G6PD results are not limited to POC tests. For context, a  
353 recent report from the College of American Pathologists (CAP) highlights challenges with the accurate  
354 diagnosis of specimens with intermediate G6PD activity in current reference clinical laboratory testing.<sup>11</sup>  
355 Among laboratories participating in the CAP proficiency testing, 12.5% of those conducting quantitative  
356 reference testing misclassified an intermediate specimen as normal, and 47.8% of those conducting  
357 qualitative testing misclassified it as normal.<sup>11</sup> These findings suggest that misclassifications of G6PD  
358 intermediate specimens are not unique to POC tests and that accurate classification of this group is a  
359 challenge in clinical laboratory testing.

360 The specificity of a POC G6PD test is also important when considering performance, as such tests may  
361 result in valuable treatment options being withheld from individuals without contraindications. Because  
362 of the typically low prevalence of G6PD deficiency in many populations, any decrease in specificity will  
363 significantly reduce the positive predictive power of the test with a significant proportion of G6PD  
364 deficient and intermediate cases assigned by the POC test actually being G6PD normal individuals. This  
365 was observed in the data presented here, where false deficient or intermediate misclassifications on the  
366 STANDARD G6PD Test were more common than false normal results. Unpublished data from settings  
367 where the STANDARD G6PD test has been scaled up and used outside the context of closely monitored  
368 clinical studies indicates that the proportion of false deficient and intermediate cases appears to increase.  
369 In the context of malaria, an overestimation of G6PD deficiency may prompt concerns about  
370 unnecessarily restricting access to radical cure and higher levels of onward transmission and relapses.

### 371 **Implications for malaria programs and future research**

372 Results from this pooled performance analysis will inform future implementation and operational research  
373 efforts for this test. One recent usability study conducted among intended test users from three high  
374 malaria burden settings found that, with appropriate training, the test can be used in clinics managing  
375 malaria cases.<sup>41</sup> Recent studies also suggest that the incorporation of the test into *P. vivax* case  
376 management in Brazil and Laos is cost effective; however, factors such as clinic case burdens and G6PD  
377 deficiency prevalence are important considerations.<sup>42,43</sup> Together, these performance, usability, and cost-  
378 effectiveness findings suggest that the STANDARD G6PD Test can be used in malaria endemic settings

379 to support G6PD classification and significantly reduce the risk of drug induced hemolysis when  
380 prescribing primaquine or tafenoquine, as well as other drugs such as rasburicase.<sup>44</sup>

381 However, the positive predictive power of the test among this population, where a significant proportion  
382 of individuals classified as G6PD deficient by the STANDARD test are in fact normal represents an  
383 operational challenge in settings where confirmatory testing cannot be conducted. As is common for  
384 many POC tests, confirmatory testing at a reference laboratory is also recommended if the test indicates a  
385 positive result for the disease status.<sup>38,45</sup> However, where a POC test has the most clinical utility, access to  
386 reference confirmatory testing is unlikely. One must consider how to appropriately counsel patients  
387 regarding the interpretation of their results.

388 This and the above limitations in test sensitivity need to be considered in the overall risk benefit  
389 assessment of G6PD screening at the point of care, which should also take into consideration local G6PD  
390 prevalence and vivax epidemiology as well as other drug eligibility criteria. Additional safety and  
391 operational studies may be warranted. Future operational studies should investigate whether testing  
392 strategies that involve repeat testing over two or three consecutive occasions can improve confirmation of  
393 true G6PD deficient cases and the effective positive predictive value specially in settings with low  
394 prevalence in G6PD deficiency. Additionally, given the extremely high negative predictive value (100%  
395 for individuals >30% G6PD activity), exploring approaches to retain patients' G6PD test results could  
396 reduce the need for repeat testing for the vast majority of the population, potentially leading to significant  
397 cost savings. Finally, the feasibility of using the G6PD test at the community level where malaria care-  
398 seeking often takes place will be critical to inform adoption strategies and scale.

### 399 **Limitations**

400 There are limitations to this analysis. The different studies contributing to this analysis were not originally  
401 designed as a multi-center clinical study, and this pooled analysis was not prospectively planned for all  
402 studies. However, the homogeneity in the designs of the included studies with regard to testing methods,  
403 data collection, and reporting allows for combining of the data. Importantly, all included studies used one  
404 of two compatible reference assays, the Trinity or the Point Scientific spectrophotometric reagent kits,  
405 which are based on the same chemistry.<sup>46</sup> Further, a systematic literature search was not employed to  
406 identify included studies. Lastly, our analysis includes fewer data generated from capillary specimens  
407 than venous specimens. However, studies that evaluated test performance on capillary specimens included  
408 several that were collected from POC settings in malaria endemic countries—Ethiopia, India, and  
409 Brazil—and specifically clinics managing malaria cases.

410 In summary, this pooled analysis supports the use of the STANDARD G6PD Test in near-patient settings  
411 where rapid turnaround screening for G6PD status is needed to inform patient care and has previously  
412 been unavailable. Operational and costing considerations should inform uptake of the test in specific  
413 settings.<sup>47</sup>

414

415

## 416 **Funding**

417 The Brazil, Ethiopia, India, Thailand, UK, and US studies were funded by the United Kingdom’s Foreign,  
418 Commonwealth & Development Office (FCDO), grant number 204139 and, by the Bill & Melinda Gates  
419 Foundation [OPP1107113, OPP1054404 and OPP1164105]. The FCDO and Bill & Melinda Gates  
420 Foundation awards to PATH support the availability of point-of-care tests for G6PD deficiency.

421 GB, CSC, and FN work at the Shoklo Malaria Research Unit, part of the Mahidol Oxford University  
422 Research Unit supported by the Wellcome Trust Mahidol Major Overseas Programme–Thailand Unit  
423 (Grant Number 220211). For the purpose of Open Access, the authors have applied a CC BY public  
424 copyright license to any author accepted manuscript version arising from this submission

425 RNP and the Bangladesh study were funded by the Wellcome Trust (Senior Fellowship in Clinical  
426 Science, 200909), BL is funded by the Australian Department of Foreign Affairs and Trade, RNP is  
427 funded by the Bill & Melinda Gates Foundation (OPP1054404 and OPP1164105).

428 MVGL and WMM are funded by Brazilian CNPq.

429 Under the grant conditions of the Gates Foundation, a Creative Commons Attribution 4.0 Generic License  
430 has been assigned to the Author Accepted Manuscript version that might arise from this submission. The  
431 findings and conclusions contained within are those of the authors and do not necessarily reflect the  
432 positions of FCDO or the Gates Foundation. The funders had no role in study design, data collection and  
433 analysis, decision to publish, or preparation of the manuscript.

434 Neither PATH, nor the co-authors have any financial interests in the commercial availability of any of the  
435 products discussed in this article. All authors read the journal’s authorship statement. All authors have  
436 read the journal’s policy on conflict of interest and do not have a conflict of interest to disclose



437 **Tables**438 **Table 1. Summary of demographics.**

|   | Bangladesh <sup>a</sup> | Brazil <sup>b</sup>               | Ethiopia                          | India                             | UK <sup>c</sup>     | US (2021) <sup>c</sup>            | Contrived Specimens <sup>c</sup> | US (2019) <sup>d</sup> | Thailand <sup>d</sup> | Total n (%)  |
|---|-------------------------|-----------------------------------|-----------------------------------|-----------------------------------|---------------------|-----------------------------------|----------------------------------|------------------------|-----------------------|--------------|
| <b>Specimen type</b>                    | Fresh venous K2EDTA     | Fresh capillary and venous K2EDTA | Fresh capillary and venous K2EDTA | Fresh capillary and venous K2EDTA | Fresh venous K2EDTA | Fresh capillary and venous K2EDTA | Contrived venous                 | Fresh venous K2EDTA    | Frozen venous K2EDTA  |              |
| Final Analytic population, n            | 108                     | 1,736                             | 1,015                             | 951                               | 167                 | 623                               | 95                               | 174                    | 150                   | 5,019        |
| Capillary Analytic population, n        | N/A                     | 1,693                             | 1,009                             | 889                               | N/A                 | 621                               | N/A                              | N/A                    | N/A                   | 4,212        |
| Venous Analytic population, n           | 108                     | 1,662                             | 1,015                             | 860                               | 167                 | 613                               | 95                               | 174                    | 150                   | 4,844        |
| <b>Sex, n (%)</b>                       |                         |                                   |                                   |                                   |                     |                                   |                                  |                        |                       |              |
| Female                                  | 81 (75.0)               | 948 (54.6)                        | 476 (46.9)                        | 345 (36.3)                        | 87 (52.1)           | 309 (49.6)                        | 90 (97.4)                        | 73 (41.9)              | 108 (72.0)            | 2,517 (50.2) |
| Male                                    | 27 (25.0)               | 788 (45.4)                        | 539 (53.1)                        | 606 (63.7)                        | 80 (47.9)           | 314 (50.4)                        | 5 (5.3)                          | 101 (58.1)             | 42 (28.0)             | 2,502 (49.8) |
| <b>G6PD status,<sup>e</sup> n (%)</b>   |                         |                                   |                                   |                                   |                     |                                   |                                  |                        |                       |              |
| Deficient < 30%                         | 30 (27.8)               | 59 (3.4)                          | 12 (1.2)                          | 27 (2.8)                          | 10 (6.0)            | 46 (7.4)                          | 3 (3.2)                          | 25 (14.4)              | 54 (36.0)             | 266 (5.3)    |
| Intermediate 30%–70%                    | 21 (19.4)               | 35 (2.0)                          | 19 (1.8)                          | 17 (1.8)                          | 10 (6.0)            | 17 (2.7)                          | 58 (61.1)                        | 10 (5.7)               | 46 (30.7)             | 233 (4.6)    |
| Normal >70%                             | 57 (52.8)               | 1,642 (94.6)                      | 984 (97.0)                        | 907 (95.4)                        | 147 (88.0)          | 560 (89.9)                        | 34 (35.8)                        | 139 (79.9)             | 50 (33.3)             | 4,520 (90.1) |
| <b>Anemia status,<sup>f</sup> n (%)</b> |                         |                                   |                                   |                                   |                     |                                   |                                  |                        |                       |              |
| Non/mild                                | N/A                     | 831 (47.9)                        | 473 (46.6)                        | 360 (37.9)                        | N/A                 | 410 (65.8)                        | 81 (85.3)                        | N/A                    | 143 (95.3)            | 2,298 (45.8) |

|  |             |              |            |            |             |            |           |             |         |              |
|--|-------------|--------------|------------|------------|-------------|------------|-----------|-------------|---------|--------------|
| Moderate                                 | N/A         | 83 (4.8)     | 1 (0.1)    | 91 (9.6)   | N/A         | 23 (3.7)   | 11 (11.6) | N/A         | 7 (4.7) | 216 (4.3)    |
| Severe                                   | N/A         | 10 (0.6)     | 0 (0)      | 30 (3.2)   | N/A         | 1 (0.2)    | 3 (3.2)   | N/A         | 0 (0)   | 44 (0.9)     |
| Missing                                  | 108 (100.0) | 812 (46.8)   | 541 (53.3) | 470 (49.4) | 167 (100.0) | 189 (30.3) | 0 (0)     | 174 (100.0) | 0 (0)   | 2,461 (49.0) |
| <b>Malaria result,<sup>a</sup> n (%)</b> |             |              |            |            |             |            |           |             |         |              |
| <i>P. falciparum</i>                     | N/A         | 12 (0.7)     | 27 (2.7)   | 29 (3.1)   | N/A         | N/A        | N/A       | N/A         | N/A     | 68 (1.4)     |
| <i>P. vivax</i>                          | N/A         | 199 (11.5)   | 0 (0.0)    | 242 (25.5) | N/A         | N/A        | N/A       | N/A         | N/A     | 441 (8.8)    |
| <i>P. falciparum/ P. vivax</i>           | N/A         | 40 (2.3)     | 0 (0.0)    | 1 (0.1)    | N/A         | N/A        | N/A       | N/A         | N/A     | 41 (0.8)     |
| Negative                                 | N/A         | 1,484 (85.5) | 988 (97.3) | 679 (71.4) | N/A         | N/A        | N/A       | N/A         | N/A     | 3,151 (62.8) |

a. Data published within Alam et al., 2018.

b. Data published within Zobrist et al., 2021.

c. Data published within Pal et al., 2021.

d. Data published within Pal et al., 2019.

e. G6PD status as determined by the spectrophotometric G6PD reference test on venous specimens, based on the specified activity thresholds.

f. Anemia status as measured by CBC in accordance with published clinically relevant Hb concentration thresholds from WHO. The non- and mild anemia categories were combined based on the clinical significance of moderate or severe anemia diagnoses, consistent with the uses of other quantitative devices for the determination of Hb concentration at the point of care. Samples for which only HemoCue Hb 201+ results were available are not included in this summary. Additionally, samples from Bangladesh were not included because of the limitations in the granularity of the data available.

g. Microscopy or rapid diagnostic test positive at recruitment.

439  
440  
441  
442  
443  
444  
445  
446  
447  
448

449 **Table 2. Adjusted G6PD normal male median (AMM) and analytical population male medians on the reference assay at the Porto Velho,**  
 450 **Brazil, and Kolkata, India, sites, by *P. vivax* malaria status.**

|  | <b>Porto Velho, Brazil</b>                           | <b>Kolkata, India</b>                                |
|--|--|--|
| <b>AMM</b>   | <b>N=36</b>  | <b>N=36</b>  |
| AMM Normal Males<br>Median 100% (95% CI)                 | 8.9<br>(8.6–9.4)                                     | 8.56<br>(7.9–9.1)                                    |
| AMM <i>P. vivax</i> Normal Males<br>Median 100% (95% CI) | 8.7<br>(7.8 – 9.4)                                   | 8.21<br>(7.6 – 9.3)                                  |
| P value  | 0.35   | 0.24   |
| <b>All Normal Males (analytical population)</b>          | <b>N=368 (all)</b><br><b>N=114 (<i>P. vivax</i>)</b> | <b>N=582 (all)</b><br><b>N=197 (<i>P. vivax</i>)</b> |
| All Normal Males<br>Median 100% (95% CI)                 | 9.1<br>(8.3 – 10.1)                                  | 8.7<br>(7.7 – 10.0)                                  |
| All <i>P. vivax</i> Normal Males<br>Median 100% (95% CI) | 8.9<br>(8.1 – 9.8)                                   | 8.2<br>(7.3 – 9.4)                                   |
| P value  | 0.08   | 0.001  |

451

452

453 **Table 3. Summary diagnostic performance of the STANDARD G6PD Test for identifying G6PD deficient males and females and females**  
 454 **with intermediate G6PD activity, by specimen type, in all study participants and in *P. vivax* cases only.**

| Specimen type                                     | Cases              |                       |                 | Performance for G6PD deficient males and females |                      | Performance for G6PD intermediate females (> 30, ≤ 70%) |                      | 3 x 3 overall percent agreement (95% CI) | Negative predictive value female > 60% (95% CI) |
|---|--------------------|-----------------------|-----------------|--|----------------------|---|----------------------|--|---|
|   | Deficient cases, n | Intermediate cases, n | Normal cases, n | Sensitivity (95% CI)                             | Specificity (95% CI) | Sensitivity (95% CI)                                    | Specificity (95% CI) |  |   |
| Capillary   | 143                | 79                    | 3990            | 100.0 (97.5–100.0)                               | 98.1 (97.6–98.5)     | 77.0 (66.8–85.4)  | 92.8 (91.6–93.9)     | 94.8 (94.1–95.5)                         | 99.6 (99.1 – 99.8)                              |
| Venous (without contrived)                        | 259                | 110                   | 4380            | 100.0 (98.6–100.0)                               | 97.6 (97.1–98.0)     | 86.6 (80.6–91.3)  | 94.4 (93.3–95.3)     | 94.8 (94.2–95.4)                         | 99.5 (99.0 – 99.7)                              |
| Venous (with contrived)                           | 262                | 152                   | 4430            | 100.0 (98.6–100.0)                               | 96.7 (96.1–97.2)     | 89.0 (85.4–93.6)  | 93.9 (92.8–94.9)     | 93.8 (93.1–94.5)                         | -   |
| <b><i>P. vivax</i>–infected participants only</b> |                    |                       |                 |  |                      |   |                      |  |   |
| Capillary   | 10                 | 9                     | 377             | 100.0 (69.2–100.0)                               | 99.0 (97.4–99.7)     | 100.0 (39.8–100.0)                                      | 93.3 (86.7–97.3)     | 96.2 (93.8–97.9)                         | -   |
| Venous  | 10                 | 4                     | 382             | 100.0 (69.2–100.0)                               | 97.7 (95.6–98.9)     | 100.0 (39.8–100.0)                                      | 87.3 (79.2–93.0)     | 96.2 (93.8–97.9)                         | -   |

455

456

457 **Table 4. 2 x 2 and 3 x 3 tables for males and female G6PD classifications respectively by the reference assay (columns) and by the**  
 458 **STANDARD G6PD test (rows).** 30% and 70% normal G6PD activity thresholds were used to classify G6PD deficient and intermediate status,  
 459 respectively, with the reference spectrophotometric assay. Manufacturer thresholds on the STANDARD G6PD test were used to classify G6PD  
 460 deficient and intermediate status.

| <b>STANDARD G6PD Test Classification</b> | <b>Reference G6PD assay classification</b> |                     |               | <b>Total</b> |
|--|--|---------------------|---------------|--------------|
| <b>Capillary: Male</b>                   |  |                     |               |              |
|  | <b>Deficient</b>                           | <b>Normal</b>       |               | <b>Total</b> |
| <b>Deficient</b>                         | 134  | 30                  |               | 164          |
| <b>Normal</b>                            | 0  | 2018                |               | 2018         |
| <b>Total</b>                             | 134  | 2048                |               | 2182         |
| <b>Capillary: Female</b>                 |  |                     |               |              |
|  | <b>Deficient</b>                           | <b>Intermediate</b> | <b>Normal</b> | <b>Total</b> |
| <b>Deficient</b>                         | 9  | 30                  | 19            | 58           |
| <b>Intermediate</b>                      | 0  | 37                  | 120           | 157          |
| <b>Normal</b>                            | 0  | 20                  | 1795          | 1815         |
| <b>Total</b>                             | 9  | 87                  | 1934          | 2030         |
| <b>Venous*: Male</b>                     |  |                     |               |              |
|  | <b>Deficient</b>                           | <b>Normal</b>       |               | <b>Total</b> |
| <b>Deficient</b>                         | 205  | 34                  |               | 239          |
| <b>Normal</b>                            | 0  | 2144                |               | 2144         |
| <b>Total</b>                             | 205  | 2178                |               | 2383         |
| <b>Venous*: Female</b>                   |  |                     |               |              |
|  | <b>Deficient</b>                           | <b>Intermediate</b> | <b>Normal</b> | <b>Total</b> |
| <b>Deficient</b>                         | 57   | 111                 | 7             | 175          |
| <b>Intermediate</b>                      | 0  | 96                  | 125           | 221          |
| <b>Normal</b>                            | 0  | 23                  | 2042          | 2065         |
| <b>Total</b>                             | 57   | 230                 | 2174          | 2461         |

461 \* Including contrived specimens

462

463 **Table 5. Performance indicators applying the 6.0 U/g Hb threshold on the STANDARD G6PD Test for deficient and intermediate females**  
 464 **with G6PD activity levels between 0% and 40%, 50%, 60%, 65%, and 70% for capillary specimens.**

|                                    | % G6PD activity (reference assay) |                       |                       |                      |                       |
|------------------------------------|-----------------------------------|-----------------------|-----------------------|----------------------|-----------------------|
|                                    | ≤ 70%                             | ≤ 65%                 | ≤ 60%                 | ≤ 50%                | ≤ 40%                 |
| Sensitivity (95% CI)               | 79.2<br>(69.7 – 86.8)             | 84.6<br>(74.7 – 91.8) | 88.1<br>(77.8 – 94.7) | 92.3<br>(79.1–98.4)  | 100.0<br>(83.9–100.0) |
| Number of false normals            | 20                                | 12                    | 8                     | 3                    | 0                     |
| Negative predictive power (95% CI) | 98.9<br>(98.3–99.3)               | 99.3<br>(98.8–99.7)   | 99.6<br>(99.1–99.8)   | 99.8<br>(99.5–100.0) | 100.0<br>(99.8–100.0) |

465

## 466 References

- 467 1. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. *Blood*.  
468 2020;136(11):1225-1240. doi:10.1182/blood.2019000944
- 469 2. Luzzatto L, Arese P. Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. *N Engl J Med*.  
470 2018;378(1):60-71. doi:10.1056/nejmra1708111
- 471 3. Aydemir D, Dağlıoğlu G, Candevir A, et al. COVID-19 may enhance risk of thrombosis and  
472 hemolysis in the G6PD deficient patients. *Nucleosides Nucleotides Nucleic Acids*. 2021;40(5):505-  
473 517. doi:10.1080/15257770.2021.1897457
- 474 4. Elalfy M, Adly A, Eltonbary K, et al. Management of children with glucose-6-phosphate  
475 dehydrogenase deficiency presenting with acute haemolytic crisis during the SARs-COV-2  
476 pandemic. *Vox Sang*. 2022;117(1):80-86. doi:10.1111/vox.13123
- 477 5. Dean L, Kane M. *Rasburicase Therapy and G6PD and CYB5R Genotype*. National Center for  
478 Biotechnology Information (US); 2020. Accessed May 13, 2022.  
479 <https://www.ncbi.nlm.nih.gov/books/NBK562585/>
- 480 6. Chu CS, Hwang J. Tafenoquine: a toxicity overview. *Expert Opin Drug Saf*. 2021;20(3):349-362.  
481 doi:10.1080/14740338.2021.1859476
- 482 7. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females  
483 heterozygous for G6PD deficiency. *Malar J*. 2018;17(1):101. doi:10.1186/s12936-018-2248-y
- 484 8. Cunningham AD, Hwang S, Mochly-Rosen D. G6PD deficiency and the need for a novel treatment  
485 to prevent kernicterus. *Clin Perinatol*. 2016;43(2):341-354. doi:10.1016/j.clp.2016.01.010
- 486 9. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency and severe neonatal  
487 hyperbilirubinemia: a complexity of interactions between genes and environment. *Semin Fetal*  
488 *Neonatal Med*. 2010;15(3):148-156. doi:10.1016/j.siny.2009.10.007
- 489 10. Olusanya BO, Emokpae AA, Zamora TG, Slusher TM. Addressing the burden of neonatal  
490 hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency.  
491 *Acta Paediatr Oslo Nor 1992*. 2014;103(11):1102-1109. doi:10.1111/apa.12735
- 492 11. Genzen JR, Nwosu A, Long T, Murphy H, Alter DN. An International Survey of Glucose-6-  
493 Phosphate Dehydrogenase Laboratory Reporting Practices. *Arch Pathol Lab Med*. Published online  
494 January 28, 2022. doi:10.5858/arpa.2021-0276-CP
- 495 12. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic  
496 review and meta-analysis | PLOS Medicine. Accessed May 13, 2022.  
497 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003084>
- 498 13. Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-Care Testing  
499 for G6PD Deficiency: Opportunities for Screening. *Int J Neonatal Screen*. 2018;4(4):34.  
500 doi:10.3390/ijns4040034
- 501 14. World Health Organization. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax  
502 radical cure. Published online 2018. Licence: CC BY-NC-SA 3.0 IGO.


- 503 15. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase  
504 deficiency testing: Divergent policies and practices in malaria endemic countries. *PLoS Negl Trop*  
505 *Dis.* 2018;12(4):e0006230. doi:10.1371/journal.pntd.0006230
- 506 16. Ley B, Satyagraha AW, Rahmat H, et al. Performance of the Access Bio/CareStart rapid diagnostic  
507 test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and  
508 meta-analysis. *PLOS Med.* 2019;16(12):e1002992. doi:10.1371/journal.pmed.1002992
- 509 17. LaRue N, Kahn M, Murray M, et al. Comparison of Quantitative and Qualitative Tests for Glucose-6-  
510 Phosphate Dehydrogenase Deficiency. *Am J Trop Med Hyg.* 2014;91(4):854-861.  
511 doi:10.4269/ajtmh.14-0194
- 512 18. Osorio L, Carter N, Arthur P, et al. Performance of BinaxNOW G6PD deficiency point-of-care  
513 diagnostic in *P. vivax*-infected subjects. *Am J Trop Med Hyg.* 2015;92(1):22-27.  
514 doi:10.4269/ajtmh.14-0298
- 515 19. Pal S, Bansil P, Bancone G, et al. Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate  
516 Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase  
517 Deficiency Closer to the Patient. *Am J Trop Med Hyg.* 2019;100(1):213-221. doi:10.4269/ajtmh.18-  
518 0612
- 519 20. Zobrist S, Brito M, Garbin E, et al. Evaluation of a point-of-care diagnostic to identify glucose-6-  
520 phosphate dehydrogenase deficiency in Brazil. *PLoS Negl Trop Dis.* 2021;15(8):e0009649.  
521 doi:10.1371/journal.pntd.0009649
- 522 21. Alam MS, Kibria MG, Jahan N, et al. Field evaluation of quantitative point of care diagnostics to  
523 measure glucose-6-phosphate dehydrogenase activity. *PLoS ONE.* 2018;13(11):e0206331.  
524 doi:10.1371/journal.pone.0206331
- 525 22. Pal S, Myburgh J, Bansil P, et al. Reference and point-of-care testing for G6PD deficiency: Blood  
526 disorder interference, contrived specimens, and fingerstick equivalence and precision. *PLoS ONE.*  
527 2021;16(9):e0257560. doi:10.1371/journal.pone.0257560
- 528 23. Roper DR, De la Salle B, Soni V, Fletcher K, Green JA. Abrogation of red blood cell G6PD enzyme  
529 activity through Heat treatment: development of survey material for the UK NEQAS G6PD scheme.  
530 *Int J Lab Hematol.* 2017;39(3):308-316. doi:10.1111/ijlh.12627
- 531 24. Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of  
532 *Plasmodium vivax* Malaria. *N Engl J Med.* 2019;380(3):215-228. doi:10.1056/NEJMoa1710775
- 533 25. Calvaresi EC, Genzen JR. Evaluating Percentage-Based Reporting of Glucose-6-Phosphate  
534 Dehydrogenase (G6PD) Enzymatic Activity. *Am J Clin Pathol.* 2020;154(2):248-254.  
535 doi:10.1093/ajcp/aqaa040
- 536 26. Ley B, Bancone G, von Seidlein L, et al. Methods for the field evaluation of quantitative G6PD  
537 diagnostics: a review. *Malar J.* 2017;16(1):361. doi:10.1186/s12936-017-2017-3
- 538 27. Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination  
539 of malaria: recommendations for evaluation of G6PD tests. *Malar J.* 2013;12(1):391.  
540 doi:10.1186/1475-2875-12-391




- 541 28. World Health Organization. *Haemoglobin Concentrations for the Diagnosis of Anaemia and*  
542 *Assessment of Severity*. World Health Organization; 2011. Accessed March 15, 2021.  
543 <https://www.who.int/vmnis/indicators/haemoglobin.pdf>
- 544 29. Pfeiffer DA, Ley B, Howes RE, et al. Quantification of glucose-6-phosphate dehydrogenase activity  
545 by spectrophotometry: A systematic review and meta-analysis. *PLoS Med*. 2020;17(5):e1003084.  
546 doi:10.1371/journal.pmed.1003084
- 547 30. Ley B, Winasti Satyagraha A, Kibria MG, et al. Repeatability and reproducibility of a handheld  
548 quantitative G6PD diagnostic. *PLoS Negl Trop Dis*. 2022;16(2):e0010174.  
549 doi:10.1371/journal.pntd.0010174
- 550 31. Fu C, Luo S, Li Q, et al. Newborn screening of glucose-6-phosphate dehydrogenase deficiency in  
551 Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates. *Sci*  
552 *Rep*. 2018;8(1):833. doi:10.1038/s41598-017-17667-6
- 553 32. Riskin A, Gery N, Kugelman A, Hemo M, Spevak I, Bader D. Glucose-6-phosphate dehydrogenase  
554 deficiency and borderline deficiency: association with neonatal hyperbilirubinemia. *J Pediatr*.  
555 2012;161(2):191-6.e1. doi:10.1016/j.jpeds.2012.02.018
- 556 33. Doherty AN, Kring EA, Posey YF, Maisels MJ. Glucose-6-phosphate dehydrogenase activity levels  
557 in white newborn infants. *J Pediatr*. 2014;164(6):1416-1420. doi:10.1016/j.jpeds.2014.02.029
- 558 34. Kaplan M, Abramov A. Neonatal Hyperbilirubinemia Associated With Glucose-6-Phosphate  
559 Dehydrogenase Deficiency in Sephardic-Jewish Neonates: Incidence, Severity, and the Effect of  
560 Phototherapy. *Pediatrics*. 1992;90(3):401-405. doi:10.1542/peds.90.3.401
- 561 35. Bancone G, Gilder ME, Win E, et al. Quantitative G6PD point-of-care test can be used reliably on  
562 cord blood to identify male and female newborns at increased risk of neonatal hyperbilirubinaemia: a  
563 mixed method study. *medRxiv*. doi:10.1101/2022.07.03.22277173
- 564 36. Ley B, Alam MS, Satyagraha AW, et al. Variation in Glucose-6-Phosphate Dehydrogenase activity  
565 following acute malaria. *PLoS Negl Trop Dis*. 2022;16(5):e0010406.  
566 doi:10.1371/journal.pntd.0010406
- 567 37. Milligan R, Daher A, Villanueva G, Bergman H, Graves PM. Primaquine alternative dosing  
568 schedules for preventing malaria relapse in people with *Plasmodium vivax*. *Cochrane Database Syst*  
569 *Rev*. 2020;8:CD012656. doi:10.1002/14651858.CD012656.pub3
- 570 38. Chu CS, Bancone G, Kelley M, et al. Optimizing G6PD testing for *Plasmodium vivax* case  
571 management and beyond: why sex, counseling, and community engagement matter. *Wellcome Open*  
572 *Res*. 2020;5:21. doi:10.12688/wellcomeopenres.15700.2
- 573 39. Taylor WRJ, Thriemer K, Seidlein L von, et al. Short-course primaquine for the radical cure of  
574 *Plasmodium vivax* malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. *The*  
575 *Lancet*. 2019;394(10202):929-938. doi:10.1016/S0140-6736(19)31285-1
- 576 40. Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus Primaquine to Prevent Relapse  
577 of *Plasmodium vivax* Malaria. *N Engl J Med*. 2019;380(3):229-241. doi:10.1056/NEJMoa1802537

- 578 41. Gerth-Guyette E, Adissu W, Brito M, et al. Usability of a point-of-care diagnostic to identify glucose-  
579 6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and  
580 results interpretation. *Malar J.* 2021;20(1):307. doi:10.1186/s12936-021-03803-1
- 581 42. Aung YN, Tun STT, Vanisaveth V, Chindavongsa K, Kanya L. Cost-effectiveness analysis of G6PD  
582 diagnostic test for Plasmodium vivax radical cure in Lao PDR: An economic modelling study. *PLoS*  
583 *One.* 2022;17(4):e0267193. doi:10.1371/journal.pone.0267193
- 584 43. Brito-Sousa JD, Peixoto HM, Devine A, et al. Real-life quantitative G6PD screening in Plasmodium  
585 vivax patients in the Brazilian Amazon: A cost-effectiveness analysis. *PLoS Negl Trop Dis.*  
586 2022;16(3):e0010325. doi:10.1371/journal.pntd.0010325
- 587 44. Ganapathi M, Campbell P, Ofori K, Aggarwal V, Francis RO, Kratz A. Impact of pre-emptive rapid  
588 testing for glucose-6-phosphate dehydrogenase deficiency prior to rasburicase administration at a  
589 tertiary care centre: A retrospective study. *Br J Clin Pharmacol.* Published online April 14, 2022.  
590 doi:10.1111/bcp.15353
- 591 45. Domingo GJ, Advani N, Satyagraha AW, et al. Addressing the gender-knowledge gap in glucose-6-  
592 phosphate dehydrogenase deficiency: challenges and opportunities. *Int Health.* 2019;11(1):7-14.  
593 doi:10.1093/inthealth/ihy060
- 594 46. Alam MS, Kibria MG, Jahan N, Price RN, Ley B. Spectrophotometry assays to determine G6PD  
595 activity from Trinity Biotech and Pointe Scientific G6PD show good correlation. *BMC Res Notes.*  
596 2018;11(1):855. doi:10.1186/s13104-018-3964-7
- 597 47. Engel N, Ghergu C, Matin MA, et al. Implementing radical cure diagnostics for malaria: user  
598 perspectives on G6PD testing in Bangladesh. *Malar J.* 2021;20(1):217. doi:10.1186/s12936-021-  
599 03743-w
- 600

**Figure 1. Site-specific variation in G6PD activity among normal males on fresh capillary and venous specimens on A) the reference assay, and B) the STANDARD G6PD Test.\***



\* The UK study, which included newborns and samples with blood disorders, and the Thailand study, which was conducted on frozen samples, are not included in Figure 1.




**Figure 2. G6PD activity classification of the STANDARD G6PD and reference assays for A) males and B) females.** G6PD status classification measured by the STANDARD G6PD test is shown on the X-axis, for capillary (grey) and venous (black) specimens, respectively. Results are plotted by the reference G6PD percent activity (Y-axis). Shaded areas correspond to true G6PD normal (green), intermediate (yellow), and deficient (red) status classifications on the reference assay.


**Figure 3. Participant eligibility and outcomes for radical cure treatment options based on the results of the STANDARD G6PD Test on capillary specimens**  
 Panels A and B represent eligibility and outcomes for daily primaquine regimen. Panels C and D represent eligibility and outcomes for tafenoquine and daily primaquine, with those who are considered ineligible for tafenoquine then considered for primaquine eligibility.

**Treatment Algorithm 1: Primaquine eligibility\***

**A. STANDARD G6PD Test result and corresponding treatment eligibility**




**B. Treatment outcome when considering results of the reference assay**




**KEY**  
 Correctly received PQ  
 Correctly excluded from PQ  
 Incorrectly excluded from PQ

**Treatment Algorithm 2: Tafenoquine and primaquine eligibility\***

**C. STANDARD G6PD Test result and corresponding treatment eligibility**




**D. Treatment outcome when considering results of the reference assay**



**KEY**  
 Correctly received either TQ or PQ  
 Correctly excluded from both TQ and PQ  
 Incorrectly excluded from both TQ and PQ  
 Incorrectly received PQ instead of TQ  
 Incorrectly received TQ instead of PQ

Abbreviations: G6PD, glucose-6-phosphate-dehydrogenase; PQ, Primaquine; Hb, Hemoglobin; TQ, Tafenoquine  
 \* No other treatment eligibility criteria (e.g., age, anemia status, pregnancy status) were considered as part of the calculation.


**Supplementary Figure 1. Summary of testing and workflow of included studies.**




Abbreviations: CBC, complete blood count; FST, fluorescent spot test; G6PD, glucose-6-phosphate dehydrogenase; Hb, hemoglobin

\* CBC was available only at one site in this study.  
 \*\* The Thailand study used frozen specimens.  
 \*\*\* CBC was run at two out of three sites.


**Supplementary Figure 2. Histograms showing the distribution of G6PD activities in the study population according to A) the reference assay and the STANDARD G6PD Test on B) Capillary and C) Venous specimens. The frequency is plotted in 10% increments for males and females. The 30% and 70% activity limits are indicated on each plot.**



**Supplementary Figure 3. ROC curves at 30% and 70% G6PD activity thresholds on A) capillary specimens and B) venous specimens.**




**Supplementary Figure 4. Distribution of false normal capillary results, by study.\***



\* Red shaded areas correspond to deficient ( $\leq 30\%$ ) reference assay values, and yellow shaded areas correspond to intermediate (30-70%) reference assay values, with darker shading at lower percent activity.

**Supplementary Figure 5. Regression analysis of STANDARD G6PD Test total hemoglobin measurement on A) capillary specimens, and B) venous specimens compared to complete blood count**

A) Capillary



**Supplementary Figure 5. Regression analysis of STANDARD G6PD Test total hemoglobin measurement on A) capillary specimens, and B) venous specimens compared to complete blood count**

B) Venous

